Improved anticancer delivery of paclitaxel by albumin surface modification of PLGA nanoparticles

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Esfandyari Manesh, Mehdi ^a   Mostafavi, Seyed Hossein ^a,b,c   Majidi, Reza Faridi ^c   Koopaei, Mona Noori ^a   Ravari, Nazanin Shabani ^a   Amini, Mohsen ^a   Darvishi, Behrad ^a,c   Ostad, Seyed Nasser ^c   Atyabi, Fatemeh ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b University of California Riverside   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Albumin; Drug delivery; Paclitaxel; PLGA; Surface modified nanoparticles

Indexed keywords

ALBUMIN CONJUGATE; DRUG CARRIER; HUMAN SERUM ALBUMIN; MALEIMIDE DERIVATIVE; PACLITAXEL; POLYGLACTIN; THIOL GROUP; ANTINEOPLASTIC AGENT; LACTIC ACID; NANOCONJUGATE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SERUM ALBUMIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL VIABILITY; CIRCULATION; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; RETICULOENDOTHELIAL SYSTEM; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HALF LIFE TIME; HUMAN; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; HALF-LIFE; HUMANS; LACTIC ACID; NANOCONJUGATES; PACLITAXEL; PARTICLE SIZE; POLYGLYCOLIC ACID; SERUM ALBUMIN;

EID: 84928620265     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-015-0107-8     Document Type: Article

References (27)

1. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-20.
2. Langer R. Drug delivery and targeting. Nature. 1998;392:5-10.
3. Koopaei MN, Khoshayand MR, Mostafavi SH, Amini M, Khorramizadeh MR, Jeddi Tehrani M, et al. Docetaxel loaded PEG-PLGA nanoparticles: optimized drug loading, in-vitro Cytotoxicity and in-vivo Antitumor Effect. Iran J Pharm Res. 2014;13:819-33.
4. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed Nanotechnol, Biol Med. 2005;1:193-212.
5. Koopaei MN, Maghazei MS, Mostafavi SH, Jamalifar H, Samadi N, Amini M, et al. Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles. Daru. 2012;20:92-9.
6. Sourabhan S, Kaladhar K, Chandra PS. Method to enhance the encapsulation of biologically active molecules in PLGA nanoparticles. Trends Biomater Artif Organs. 2009;22:211-5.
7. Mostafavi SH, Aghajani M, Amani A, Darvishi B, Noori Koopaei M, Pashazadeh AM, et al. Optimization of paclitaxel-loaded poly (d, l-lactide-co-glycolide-N-p-maleimido benzoic hydrazide) nanoparticles size using artificial neural networks. Pharm Dev Technol. 2014;1:1-9.
8. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2012;148:135-46.
9. Park K. Questions on the role of the EPR effect in tumor targeting. J Control Release. 2013;172:391.
10. Fang J, Sawa T, Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol. 2003;519:29-49.
11. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74:47-61.
12. Hirsjarvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol. 2011;8:188-96.
13. Okamura Y, Fujie T, Maruyama H, Handa M, Ikeda Y, Takeoka S. Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide. Transfusion. 2007;47:1254-62.
14. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283-318.
15. He X, Ma J, Mercado AE, Xu W, Jabbari E. Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly (lactide-co-glycolide ethylene oxide fumarate) nanoparticles. Pharm Res. 2008;25:1552-62.
16. Marcucci F, Lefoulon FO. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discov Today. 2004;9:219-28.
17. Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv. 2013;4:421-3.
18. Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 2010;150:2-22.
19. Weber C, Reiss S, Langer K. Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. Int J Pharm. 2000;211:67-78.
20. Fonseca C, Simões S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002;83:273-86.
21. Wang YM, Sato H, Adachi I, Horikoshi I. Preparation and characterization of poly (lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, Taxol. Chem Pharm Bull. 1996;44:1935-40.
22. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:R1-4.
23. Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA "paclitaxel microspheres. Biomaterials. 2007;28:3236-44.
24. Tessmar J, Mikos A, Gopferich A. The use of poly (ethylene glycol)-block-poly (lactic acid) derived copolymers for the rapid creation of biomimetic surfaces. Biomaterials. 2003;24:4475-86.
25. Manchanda R, Fernandez-Fernandez A, Nagesetti A, McGoron AJ. Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. Colloids Surf B: Biointerfaces. 2009;75:260-7.
26. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325:172-9.
27. Gindy ME, Ji S, Hoye TR, Panagiotopoulos AZ, Prud'homme RK. Preparation of poly (ethylene glycol) protected nanoparticles with variable bioconjugate ligand density. Biomacromolecules. 2008;9:2705-11.